BRPI1014197A2 - combinação antitumoral que compreende o ave8062 e o sorafenib - Google Patents
combinação antitumoral que compreende o ave8062 e o sorafenibInfo
- Publication number
- BRPI1014197A2 BRPI1014197A2 BRPI1014197A BRPI1014197A BRPI1014197A2 BR PI1014197 A2 BRPI1014197 A2 BR PI1014197A2 BR PI1014197 A BRPI1014197 A BR PI1014197A BR PI1014197 A BRPI1014197 A BR PI1014197A BR PI1014197 A2 BRPI1014197 A2 BR PI1014197A2
- Authority
- BR
- Brazil
- Prior art keywords
- ave8062
- sorafenib
- antitumor combination
- antitumor
- combination
- Prior art date
Links
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 title 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 title 1
- 229950003600 ombrabulin Drugs 0.000 title 1
- 229960003787 sorafenib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0902210A FR2945210B1 (fr) | 2009-05-07 | 2009-05-07 | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
| PCT/FR2010/050874 WO2010128259A1 (fr) | 2009-05-07 | 2010-05-06 | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014197A2 true BRPI1014197A2 (pt) | 2016-04-26 |
Family
ID=41402172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014197A BRPI1014197A2 (pt) | 2009-05-07 | 2010-05-06 | combinação antitumoral que compreende o ave8062 e o sorafenib |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20120108641A1 (pt) |
| EP (1) | EP2427185A1 (pt) |
| JP (1) | JP2012526090A (pt) |
| KR (1) | KR20120023754A (pt) |
| CN (1) | CN102438608A (pt) |
| AR (1) | AR076848A1 (pt) |
| AU (1) | AU2010244254A1 (pt) |
| BR (1) | BRPI1014197A2 (pt) |
| CA (1) | CA2761146A1 (pt) |
| CL (1) | CL2011002782A1 (pt) |
| CO (1) | CO6390102A2 (pt) |
| CR (1) | CR20110573A (pt) |
| DO (1) | DOP2011000335A (pt) |
| EA (1) | EA201171366A1 (pt) |
| EC (1) | ECSP11011440A (pt) |
| FR (1) | FR2945210B1 (pt) |
| IL (1) | IL216133A0 (pt) |
| MA (1) | MA33346B1 (pt) |
| MX (1) | MX2011011767A (pt) |
| NI (1) | NI201100191A (pt) |
| PE (1) | PE20120323A1 (pt) |
| SG (1) | SG175895A1 (pt) |
| TN (1) | TN2011000551A1 (pt) |
| TW (1) | TW201043225A (pt) |
| UY (1) | UY32618A (pt) |
| WO (1) | WO2010128259A1 (pt) |
| ZA (1) | ZA201108110B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2481404A1 (en) * | 2010-11-15 | 2012-08-01 | Sanofi | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
| BR112012031917A2 (pt) * | 2010-06-18 | 2017-11-28 | Sanofi Sa | combinação antitumoral compreendendo ombrabulina, um derivado de taxano e um derivado de platina |
| FR2968557A1 (fr) * | 2010-12-09 | 2012-06-15 | Sanofi Aventis | Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab |
| EP3111937B1 (en) | 2011-07-08 | 2020-06-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
| FR2978663A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
| FR2978662A1 (fr) | 2011-08-01 | 2013-02-08 | Sanofi Sa | Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie |
| CA2942039A1 (en) * | 2014-02-18 | 2015-08-27 | Health Research, Inc. | Combination therapy for hepatocellular carcinoma |
| KR102272993B1 (ko) * | 2019-07-09 | 2021-07-06 | 충남대학교산학협력단 | 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| HUP0102521A3 (en) * | 1998-04-03 | 2003-08-28 | Ajinomoto Kk | Antitumor agents comprising a stilbene derivative and a platinum coordination compound |
| JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| WO2003000290A1 (en) * | 2001-06-25 | 2003-01-03 | Ajinomoto Co., Inc. | Antitumor agents |
| PT1580188E (pt) * | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aril-ureias como inibidores de cinases |
| FR2838437B1 (fr) | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | Procedes de preparation de combretastatines |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
-
2009
- 2009-05-07 FR FR0902210A patent/FR2945210B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-06 AU AU2010244254A patent/AU2010244254A1/en not_active Abandoned
- 2010-05-06 WO PCT/FR2010/050874 patent/WO2010128259A1/fr not_active Ceased
- 2010-05-06 BR BRPI1014197A patent/BRPI1014197A2/pt not_active IP Right Cessation
- 2010-05-06 PE PE2011001907A patent/PE20120323A1/es not_active Application Discontinuation
- 2010-05-06 CN CN2010800199231A patent/CN102438608A/zh active Pending
- 2010-05-06 TW TW099114579A patent/TW201043225A/zh unknown
- 2010-05-06 JP JP2012509078A patent/JP2012526090A/ja active Pending
- 2010-05-06 CA CA2761146A patent/CA2761146A1/fr not_active Abandoned
- 2010-05-06 AR ARP100101542A patent/AR076848A1/es not_active Application Discontinuation
- 2010-05-06 MA MA34428A patent/MA33346B1/fr unknown
- 2010-05-06 EP EP10727467A patent/EP2427185A1/fr not_active Withdrawn
- 2010-05-06 KR KR1020117029137A patent/KR20120023754A/ko not_active Withdrawn
- 2010-05-06 MX MX2011011767A patent/MX2011011767A/es not_active Application Discontinuation
- 2010-05-06 SG SG2011081361A patent/SG175895A1/en unknown
- 2010-05-06 EA EA201171366A patent/EA201171366A1/ru unknown
- 2010-05-07 UY UY0001032618A patent/UY32618A/es not_active Application Discontinuation
-
2011
- 2011-10-31 TN TNP2011000551A patent/TN2011000551A1/fr unknown
- 2011-11-02 DO DO2011000335A patent/DOP2011000335A/es unknown
- 2011-11-03 IL IL216133A patent/IL216133A0/en unknown
- 2011-11-03 CR CR20110573A patent/CR20110573A/es unknown
- 2011-11-03 US US13/288,236 patent/US20120108641A1/en not_active Abandoned
- 2011-11-04 CO CO11149814A patent/CO6390102A2/es not_active Application Discontinuation
- 2011-11-04 CL CL2011002782A patent/CL2011002782A1/es unknown
- 2011-11-04 NI NI201100191A patent/NI201100191A/es unknown
- 2011-11-04 ZA ZA2011/08110A patent/ZA201108110B/en unknown
- 2011-11-07 EC EC2011011440A patent/ECSP11011440A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102438608A (zh) | 2012-05-02 |
| FR2945210B1 (fr) | 2011-07-01 |
| PE20120323A1 (es) | 2012-04-17 |
| TW201043225A (en) | 2010-12-16 |
| ECSP11011440A (es) | 2011-12-30 |
| AR076848A1 (es) | 2011-07-13 |
| ZA201108110B (en) | 2013-01-30 |
| EA201171366A1 (ru) | 2012-05-30 |
| CR20110573A (es) | 2011-12-08 |
| JP2012526090A (ja) | 2012-10-25 |
| TN2011000551A1 (fr) | 2013-05-24 |
| CO6390102A2 (es) | 2012-02-29 |
| KR20120023754A (ko) | 2012-03-13 |
| MX2011011767A (es) | 2012-02-28 |
| CA2761146A1 (fr) | 2010-11-11 |
| US20120108641A1 (en) | 2012-05-03 |
| IL216133A0 (en) | 2012-01-31 |
| UY32618A (es) | 2010-12-31 |
| NI201100191A (es) | 2012-01-16 |
| CL2011002782A1 (es) | 2012-03-30 |
| AU2010244254A1 (en) | 2011-11-24 |
| MA33346B1 (fr) | 2012-06-01 |
| DOP2011000335A (es) | 2011-12-15 |
| EP2427185A1 (fr) | 2012-03-14 |
| FR2945210A1 (fr) | 2010-11-12 |
| SG175895A1 (en) | 2011-12-29 |
| WO2010128259A1 (fr) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2019041I1 (no) | Kombinasjon av daunorubicin og cytarabin | |
| IL252398A0 (en) | cd37-binding molecules and their immunoconjugates | |
| HRP20170991T1 (hr) | Pokretni zasloni i povezani postupci | |
| IL223295A (en) | Lung cancer biomarkers and uses thereof | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| BR112013009069A2 (pt) | instrumentação unida ao paciente e métodos | |
| ZA201303028B (en) | Spacer and components therefor | |
| BR112014009050A2 (pt) | pirrolbenzodiazepinas e conjugados destas | |
| DK3597644T3 (da) | Kationiske aminlipider og anvendelser deraf | |
| ZA201307302B (en) | Cd37-binding molecules and immunoconjugates thereof | |
| DK2857634T3 (da) | Tætningsfremgangsmåde og -indretning | |
| EP2441646A4 (en) | SUPPORT AND STROLLER FOR BABY | |
| DE602008005705D1 (de) | Leitschaufel und Leitschaufelanordnung | |
| BRPI1012727A2 (pt) | transmissão utilizando pilotos comuns e dedicados | |
| FI20096058A0 (fi) | Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä | |
| BRPI1014197A2 (pt) | combinação antitumoral que compreende o ave8062 e o sorafenib | |
| BRPI1009666A2 (pt) | diferencial e alojamento | |
| FI20090142A0 (fi) | Uudet menetelmät ja tuotteet | |
| EP2547464A4 (en) | ARRANGEMENT AND VENTILATION ARRANGEMENT | |
| FR2964937B1 (fr) | Triporteur et direction de triporteur | |
| DK2536591T3 (da) | Advarselslysanordning; komponenter; og fremgangsmåder | |
| IT1400302B1 (it) | Bruciatore e forno comprendente detto bruciatore | |
| ZA201309666B (en) | Burner arrangement and burner assembly | |
| ES1071902Y (es) | Mecanismo de termosoldadura y precorte | |
| TWM389828U (en) | Easily assembly and disassembly lamp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |